Get the Daily Brief
Latest Biotech News
Groundbreaking Optical Clock Network Advances Timekeeping Precision
Researchers across six countries conducted the most extensive simultaneous comparison of optical atomic clocks, creating a network spanning thousands of kilometers. This distributed system...
AI-Driven Broad-Spectrum Coronavirus Drug Emerges from Cambridge
A multidisciplinary team at Harvard's Wyss Institute leveraged AI-enabled molecular modeling and physics-based simulations to identify and optimize bemcentinib derivatives with antiviral activity...
Pembrolizumab Approved by FDA for Perioperative Head and Neck Cancer
The U.S. Food and Drug Administration granted approval to pembrolizumab as a perioperative treatment for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1. This...
FDA Approves UroGen’s Zusduri for Low-Grade Bladder Cancer
Despite a narrowly negative advisory committee vote, the FDA approved UroGen’s hydrogel formulation for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer based on high...
ADC Therapeutics Shutters UK R&D, Cuts Workforce Amid Pipeline Setbacks
ADC Therapeutics is closing its UK research facility, discontinuing several preclinical oncology programs, and cutting its workforce by 30% following the termination of its only clinical-stage...
Pembrolizumab Approval Transforms Head and Neck Cancer Care
The FDA has approved pembrolizumab, an immune checkpoint inhibitor, for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, following the pivotal phase 3...
Anne Wojcicki Wins 23andMe Asset Auction with Nonprofit Bid
Anne Wojcicki, co-founder and former CEO of 23andMe, secured purchase of the company’s assets for $305 million through her nonprofit, TTAM Research Institute, winning a last-minute auction over...
Insmed’s $750M Follow-On Raised Post-Hypertension Data
Following clinical readouts in hypertension, biopharma firm Insmed announced plans for a $750 million follow-on public offering. The move underscores investor confidence after promising trial...
Novel Vascular Organoids Developed via Dual Transcription Activation
Scientists reported a rapid method to generate functional vascular organoids from human induced pluripotent stem cells by simultaneous activation of endothelial and mural transcription factors,...
Broadening FDA Drug Pricing Negotiations Amid Industry Pushback
The Trump administration is pressuring pharmaceutical companies to negotiate drug prices comparable to other wealthy nations, invoking a 'most-favored nation' clause. Despite awaiting drug and...
New Cooling Technology Promises Energy Efficient Data Centers
Engineers at UC San Diego developed a novel evaporative cooling system employing a porous fiber membrane that passively removes heat from electronics via capillary-driven evaporation. This...
FDA Approves UroGen’s Bladder Cancer Hydrogel Despite Advisory Vote
The FDA cleared UroGen’s hydrogel-based treatment, Zusduri (mitomycin), for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer following positive phase III trial results...
Advancements in Parkinson’s Disease: Genomic and Clinical Insights
Recent research elucidates the influence of GBA1 genetic variant severity and polygenic background on Parkinson’s disease penetrance, reflecting personalized disease risk. Additional studies...
BioNTech Acquires CureVac to End mRNA Patent Litigation
BioNTech announced an all-stock acquisition of CureVac valued at approximately $1.25 billion, ending a protracted patent dispute over mRNA vaccine technology. CureVac shareholders will receive...
Single-Cell Atlas Collaboration Targets Cancer Plasticity
The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences are collaborating to create a comprehensive single-cell atlas profiling cancer plasticity and treatment response. The...
BioNTech Buys CureVac in $1.25 Billion Stock Deal to End mRNA Lawsuit
BioNTech announced the acquisition of CureVac in an all-stock transaction valued at about $1.25 billion, resolving years of patent litigation between the two German mRNA vaccine developers. The...
Enhanced CAR-T Cells Resist Death, Boost Efficacy in Solid Tumors
Scientists engineered IFN-γ-resistant CD28 CAR-T cells that show increased survival and heightened anti-tumor activity in solid tumor models. This breakthrough overcomes a key limitation in CAR-T...
FDA Delay Limits KalVista’s On-Demand HAE Drug Approval Timeline
KalVista Pharmaceuticals reported that the FDA has delayed its decision on the company's oral on-demand treatment for hereditary angioedema, citing agency workload and limited resources. This...
BioNTech Acquires CureVac to Settle mRNA Patent Dispute
BioNTech announced an all-stock acquisition of German mRNA vaccine peer CureVac for approximately $1.25 billion. The deal, positioned as a resolution to ongoing patent litigation between the...
FDA Expands RSV Vaccine Approval for Adults
Moderna’s RSV vaccine received FDA approval to expand its use to include certain younger adults aged 18 to 59 at increased risk for RSV infection. This regulatory expansion follows recent changes...